# Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

> **NCT03005717** · PHASE2 · COMPLETED · sponsor: **Neothetics, Inc** · enrollment: 162 (actual)

## Conditions studied

- Submental Fat

## Interventions

- **DRUG:** LIPO-202
- **DRUG:** Placebo for LIPO-202

## Key facts

- **NCT ID:** NCT03005717
- **Lead sponsor:** Neothetics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-22
- **Primary completion:** 2017-06-02
- **Final completion:** 2017-06-02
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03005717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03005717, "Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03005717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*